Frankfurt - Delayed Quote EUR
Zevra Therapeutics, Inc. (1GDA.F)
At close: October 22 at 8:02 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
23,689.00
--
10,161.00
28,650.00
13,288.00
12,839.00
Cost of Revenue
5,891.00
--
222.00
2,059.00
1,305.00
2,945.00
Gross Profit
17,798.00
--
9,939.00
26,591.00
11,983.00
9,894.00
Operating Expense
92,600.00
--
34,841.00
18,862.00
16,764.00
30,231.00
Operating Income
-74,802.00
--
-24,902.00
7,729.00
-4,781.00
-20,337.00
Net Non Operating Interest Income Expense
-820.00
--
1,178.00
-115.00
-7,001.00
-6,205.00
Other Income Expense
8,993.00
--
-3,081.00
-16,135.00
-1,012.00
1,998.00
Pretax Income
-66,629.00
--
-26,805.00
-8,521.00
-12,794.00
-24,544.00
Tax Provision
177.00
--
-33.00
34.00
-34.00
-22.00
Net Income Common Stockholders
-66,806.00
--
-26,772.00
-62,897.00
-12,760.00
-24,522.00
Diluted NI Available to Com Stockholders
-66,806.00
--
-26,772.00
-62,897.00
-12,760.00
-24,522.00
Basic EPS
-1.71
-1.30
-1.20
-2.11
-3.21
--
Diluted EPS
-1.71
-1.30
-1.20
-2.11
-3.21
--
Basic Average Shares
39,281.84
35,452.46
34,488.80
29,766.35
3,980.98
--
Diluted Average Shares
39,281.84
35,452.46
34,488.80
29,766.35
3,980.98
--
Total Operating Income as Reported
-74,802.00
--
-42,565.00
7,729.00
-5,609.00
-20,337.00
Total Expenses
98,491.00
--
35,063.00
20,921.00
18,069.00
33,176.00
Net Income from Continuing & Discontinued Operation
-66,806.00
--
-26,772.00
-8,555.00
-12,760.00
-24,522.00
Normalized Income
-73,910.47
--
-23,694.70
3,223.55
-11,750.63
-26,518.20
Interest Income
3,147.00
--
1,513.00
261.00
89.00
309.00
Interest Expense
3,967.00
--
335.00
376.00
7,090.00
6,514.00
Net Interest Income
-820.00
--
1,178.00
-115.00
-7,001.00
-6,205.00
EBIT
-62,662.00
--
-26,470.00
-8,145.00
-5,704.00
-18,030.00
EBITDA
-58,689.00
--
-25,526.00
-7,888.00
-5,431.00
-17,726.00
Reconciled Cost of Revenue
5,891.00
--
222.00
2,059.00
1,305.00
2,945.00
Reconciled Depreciation
3,973.00
--
944.00
257.00
273.00
304.00
Net Income from Continuing Operation Net Minority Interest
-66,806.00
--
-26,772.00
-8,555.00
-12,760.00
-24,522.00
Total Unusual Items Excluding Goodwill
8,993.00
--
-3,081.00
-16,135.00
-1,012.00
1,998.00
Total Unusual Items
8,993.00
--
-3,081.00
-16,135.00
-1,012.00
1,998.00
Normalized EBITDA
-67,682.00
--
-22,445.00
8,247.00
-4,419.00
-19,724.00
Tax Rate for Calcs
0.00
--
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
1,888.53
--
-3.70
-4,356.45
-2.63
1.80
12/31/2019 - 6/22/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
K67.F Fortrea Holdings Inc.
17.10
-4.47%
PHG.F Pharming Group N.V.
8.05
-1.83%
2RZ.MU Poseida Therapeutics Inc
2.3060
0.00%
0QCO.IL Pharming Group N.V.
0.8348
-2.05%
GBY.MU Sangamo Therapeutics Inc
1.1704
+37.68%
PHGN.F Pharming Group N.V.
0.8360
+4.11%
RYH0.F Sareum Holdings plc
0.2580
-4.44%
RYH0.SG Sareum Holdings PLC
0.2820
-4.08%
0MGB.IL Genmab A/S
1,539.50
-1.20%
PEG.CO Pharma Equity Group A/S
0.2040
-2.86%